BLRX: BioLineRx Ltd. - Summary | Jitta

BioLineRx Ltd.

ISR:BLRX

Price
₪0.02
Loss Chance
57.9%
1.84JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
364 / 421
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (33)
Recent Business Performance (45)
Financial Strength (33)
Return to Shareholders (0)
Competitive Advantage (20)
Jitta Signs
Recent Business PerformanceEarning Growth Last Year
Cash Conversion CycleLess than 30 days
Operating MarginDeclined
New Share IssuedMore than 50% in 5 years
CapExVery High
Key Stats
Jitta Score
Jitta Line
1.84
100.00%
1.58
85.44%
2.84
95.01%
Biotechnology
n/a
100.00%
0.58
100.00%
1.38
100.00%
COMPANY DESCRIPTION
BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company’s pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.